Strong Industry Presence Icosagen has established itself as a premier European CDMO with over 25 years of experience and a diverse portfolio supporting over 100 biotech and pharma clients. Its long-standing reputation and extensive project base create opportunities for partnerships in complex protein development and production.

Recent Strategic Expansions The company’s recent investments in a new 1600 m² GMP facility and a 42.8 million euro upgrade demonstrate a commitment to expanding production capacity and R&D capabilities, making it attractive for clients seeking scalable manufacturing and innovative drug development services.

Innovative Technology Adoption Acquisition of Carterra’s antibody screening assets and development of novel mammalian cell line platforms highlight Icosagen’s focus on cutting-edge biotechnologies, offering potential collaborations in antibody discovery, diagnostics, and biologics development.

Award-Winning Reputation Recognition as Best Business and Innovator of the Year enhances Icosagen’s credibility, serving as a trust signal for prospective clients looking for innovative partners capable of revolutionizing their drug development pipelines.

Market Opportunities With a revenue range of 1 to 10 million dollars and substantial investments in GMP facilities, Icosagen is positioned to support mid-size biotech companies and startups seeking reliable, scalable, and innovative manufacturing solutions in the competitive biopharmaceutical landscape.